FDA Recommends Earlier MRI Monitoring for Leqembi (lecanemab): What Changed, Why It Matters, and the Real-World Impact

Date of FDA communication: August 28, 2025

Summary (TL;DR)

The FDA now recommends an additional, earlier brain MRI before the 3rd Leqembi infusion (previously before the 5th, 7th, and 14th). The shift follows an analysis of serious ARIA-E cases and six early-treatment fatalities, suggesting earlier imaging may detect brain swelling sooner and help clinicians pause or discontinue therapy to reduce risk. This recommendation will be added to the product label (Section 2.3). U.S. Food and Drug Administration

What exactly did FDA change?

New monitoring point: MRI between the 2nd and 3rd infusion (in addition to the existing MRIs before the 5th, 7th, and 14th infusions).
Rationale: Identify amyloid-related imaging abnormalities with edema (ARIA-E) earlier—often asymptomatic but potentially serious or life-threatening.
Label action: FDA is requiring Leqembi’s prescribing information to include the earlier MRI in the monitoring schedule (Section 2.3). U.S. Food and Drug Administration

Why was this suggested? (The evidence behind the move)

1) Post-marketing safety signal

FDA’s routine pharmacovigilance identified six fatalities early in treatment, triggering an in-depth review of serious and fatal ARIA-E cases before the 5th infusion. Among 101 serious ARIA-E cases in FAERS, 24 occurred before the 4th infusion (many symptomatic), indicating clinically meaningful events can arise well before the previously scheduled first monitoring MRI at infusion 5. U.S. Food and Drug Administration

2) Timing of ARIA-E from clinical trials

In CLARITY-AD, ARIA-E typically occurred within 3–6 months—a window that can overlap with the 3rd–6th infusions, supporting earlier surveillance. Overall ARIA-E incidence was ~12–13%, ARIA-H ~17%, with higher rates in APOE-ε4 carriers, especially homozygotes. PMC New England Journal of Medicine FDA Access Data

3) Risk stratification (APOE-ε4 and antithrombotics)

Labeling and guidance emphasize APOE-ε4 testing before initiation due to higher ARIA risk in ε4/ε4 homozygotes; severe radiographic ARIA-E and ARIA-H are substantially more frequent in this group. Concomitant antithrombotic use (mostly aspirin) did not increase ARIA risk in trial data, though intracerebral hemorrhage events are tracked closely. FDA Access Data LEQEMBI PharmGKB

What does the new monitoring timeline look like?

Baseline MRI: within 12 months before starting therapy (for comparison).
Early add-on MRI: before the 3rd infusion (new).
Ongoing MRIs: before the 5th, 7th, and 14th infusions (existing schedule).
Urgent MRI: anytime new neurological symptoms arise (e.g., headache, confusion, dizziness, vision changes, nausea, gait difficulty, aphasia, weakness, seizure). U.S. Food and Drug Administration

Impact analysis: patients, providers, payers, and trial design

Patients & caregivers

Benefit: Earlier detection of ARIA-E may allow timely pause/discontinuation, potentially preventing severe or fatal outcomes. U.S. Food and Drug Administration
Burden: One additional MRI early in the course adds time, travel, and cost—which can differentially affect access for rural/low-resource patients. (Inference based on added imaging; FDA notes the new MRI is being required on label.) U.S. Food and Drug Administration
Informed consent: Discussions should explicitly cover ARIA risks, symptom vigilance, and genotype-linked risk (APOE-ε4), aligning expectations about possible treatment interruptions. FDA Access Data PharmGKB

Treating centers & workflow

Operational load: Infusion centers must coordinate earlier imaging, tighten symptom triage protocols, and prepare for dose-hold decisions when ARIA-E is detected.
Protocols: Centers should update order sets and checklists to ensure the MRI between infusions 2 and 3 is scheduled before dose day; radiology turnaround time becomes critical. (Operational inference; aligns with FDA’s required label change.) U.S. Food and Drug Administration

Payers & health-system economics

Short-term costs: One extra MRI increases upfront costs.
Potential offsets: If earlier detection reduces severe ARIA-E, the system may avoid ER visits, hospitalizations, and ICU care, which are far costlier than an MRI. (Economic inference based on FDA’s safety rationale.) U.S. Food and Drug Administration

Clinical research & policy

Benchmarking vs. class peers: The earlier MRI schedule aligns more closely with requirements used for other anti-amyloid antibodies (e.g., more front-loaded MRIs), potentially standardizing class expectations. Reuters
Post-marketing surveillance: Reinforces the value of FAERS and real-world evidence to refine risk-minimization after launch. U.S. Food and Drug Administration

Practical guidance for clinics (checklist)

Update SOPs to include MRI before infusion #3; embed in EHR order sets. U.S. Food and Drug Administration
Genotype first: Incorporate APOE-ε4 testing into pre-initiation workflow; tailor counseling for ε4/ε4 patients. FDA Access Data PharmGKB
Symptom hotline: Create fast-track evaluation for post-infusion neurologic symptoms and urgent MRI access. U.S. Food and Drug Administration
Hold criteria: Train staff on dose-interruption and re-challenge rules per the updated USPI Section 2.3. U.S. Food and Drug Administration
Documentation: Strengthen informed consent templates to reflect earlier imaging and ARIA risk by genotype. FDA Access Data

Scientific backdrop: what we know about ARIA with lecanemab

Incidence: CLARITY-AD reported ~12–13% ARIA-E and ~17% ARIA-H in the lecanemab arm; ε4 carriers, especially homozygotes, have higher risk. New England Journal of Medicine FDA Access Data
Onset: ARIA-E clusters in the first 3–6 months, overlapping the early infusions. PMC
Severity by genotype: Severe radiographic ARIA-E/H risks are highest in ε4/ε4 vs. heterozygotes or noncarriers. Leqembi
Antithrombotics: Trial data (mostly aspirin exposure) did not show increased ARIA risk, but rare intracerebral hemorrhage occurred in both antithrombotic users and non-users. Clinical judgment remains essential. FDA Access Data LEQEMBI

What patients and caregivers should do now

Ask about the early MRI if you’re between infusions #2 and #3.
Report symptoms immediately (headache, confusion, dizziness, visual changes, nausea, gait issues, aphasia, weakness, seizure).
Discuss APOE-ε4 status and how it affects your risk and monitoring plan. U.S. Food and Drug Administration

Bottom line

The FDA’s move to add an earlier MRI before the 3rd infusion is a risk-reduction step grounded in post-marketing data showing meaningful early ARIA-E events. For clinics, it means tightened early surveillance and clearer pause rules; for patients, it may improve safety at the cost of one more scan. The change underscores how real-world pharmacovigilance refines benefit-risk after approval. U.S. Food and Drug Administration

Sources

FDA Drug Safety Communication (Aug 28, 2025): earlier MRI before 3rd infusion; six early fatalities; FAERS analysis; label update to Section 2.3; patient/HCP guidance. U.S. Food and Drug Administration
CLARITY-AD trial and label data on ARIA incidence and APOE-linked risk. New England Journal of Medicine FDA Access Data+1 Leqembi
Timing of ARIA-E (3–6 months), genotype risk amplification. PMC
Context vs. class monitoring expectations and news coverage. Reuters+1

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.